Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

Cabazitaxel significantly improved radiographic progression-free survival and overall survival in the CARD study. The study involved 62 clinical sites...

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumors. Eligible patients were adults with progressive, advanced, well-differen...

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

CH5126766 is a novel MEK-pan-RAF inhibitor. The initial development of this drug was limited by toxicity. We evaluated three intermittent oral schedul...

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

This report provides updated 4-year efficacy, initial overall survival, and late-emergent safety results. Patients aged 15 years or older with resecte...

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Trastuzumab was administered intravenously every 3 weeks for 18 doses or weekly for 9 weeks. 5-year distant metastasis-free survival rates were 98% fo...

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Epithelioid sarcoma is a rare and aggressive soft-tissue sarcomo subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependen...

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. At 24 months, progression-free survival was 77% in patien...

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Gemogenovatucel-T is an autologous tumour cell vaccine manufactured from harvested tumour tissue. It reduces expression of furin and downstream TGF-β1...

Departments

Recent Posts